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Corneal complications, secondary to corneal endothelial compromise, have been 
associated with glaucoma drainage devices (GDD) since their introduction. Such 
complications can adversely affect patients’ visual outcomes and subsequently lead 
to failure of treatment. The exact mechanism of how the drainage devices affect the 
corneal endothelium is not very well understood. The literature lacks evidence, 
specifically, for the effect of Molteno® glaucoma implants (Molteno Ophthalmic 
Limited, Dunedin, New Zealand) on the corneal endothelium. With the development 
of non-invasive, office-based instruments such as the specular microscope and 
anterior segment optical coherence tomography (AS-OCT), one can visualise the tube 
of GDD and quantitatively and qualitatively examine the corneal endothelium. 
 
This study was conducted to describe the relationship between Molteno 
implant tube positioning in the anterior chamber, and corneal endothelial 
parameters, over time. Twenty-six patients attending the Eye Department at 
Dunedin Public Hospital with previous Molteno implant surgery were enrolled over 
6-month period in 2014. Their contralateral glaucomatous eyes were used as controls 
if those eyes did not have Molteno implants. All enrolled Molteno implant eyes 
(cases) and controls underwent non-contact specular microscopy examination of 
their endothelia at central and peripheral corneal locations. These measures were 
repeated at three monthly intervals for one year. Molteno implant eyes further 
underwent AS-OCT examination to measure the geometric positioning of the tube in 
the anterior chamber in relation to the posterior surface of the cornea. At the final 
visit, a significant difference in corneal endothelial densities (ECD) was observed 
between cases and controls in central and peripheral corneal locations. In cases eyes, 
central ECD loss over 6 months was estimated around 7.2%, which was higher than 
the control group. Tube length and tube-cornea angle were associated with localised 
peripheral ECD loss in the vicinity of the Molteno tube.  
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Corneal endothelial assessment prior to Molteno implant insertion and post-
operative imaging of the tube, can be informative regarding the potential of risk 
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The corneal endothelium is essential to maintain corneal transparency by regulating 
the hydration of the cornea. To achieve this function, a minimum endothelial cell 
density is required below which the system becomes overloaded and fails to work, 
leading to corneal oedema and subsequently, decreased vision.[1] Corneal 
endothelial cell loss occurs naturally with aging but certain stressors accelerate that 
loss.[2] Such stressors include intraocular surgery – such as cataract extraction[3] and 
trabeculectomy[4], pars plana vitrectomy[5] and laser iridotomy[6]. Topical eye 
drops and their preservatives can also have a detrimental impact on the corneal 
endothelium. [7] 
Glaucoma is the second leading cause of blindness in the world but when it is 
diagnosed early, blindness is prevented. [8]Glaucoma is commonly treated medically 
using topical eye drops to reduce the intraocular pressure (IOP). Should topical 
medication fail to control the progression of glaucoma, laser treatment and surgical 
treatment is considered.[9] The most commonly performed glaucoma surgery is 
trabeculectomy, which has a reasonably high success rate. Glaucoma drainage 
devices (GDD) were adopted, as an alternative to trabeculectomy, in recalcitrant 
glaucoma, or in glaucoma cases with high risk of failure of IOP control.[9, 10] After 
the Tube versus Trabeculectomy (TVT) study showed comparable success rates 
between the two procedures, many glaucoma surgeons started utilising GDD 
surgery as a primary surgical choice. [11] 
Since the introduction of glaucoma drainage devices (GDD), they have been 
associated with corneal complications.[12, 13] The TVT study described a unique 
post-operative complication to tube implantation surgery:  persistent corneal 
oedema. [14] Corneal endothelial compromise and cell loss is commonly seen after 
GDD, and this loss appears to continue at a significantly higher rate than is observed 
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with the normal aging process.[15-17] This can potentially lead to corneal 
decompensation, which carries a guarded visual prognosis. The cumulative risk of 
corneal decompensation is estimated to be 3.3%, 5 years after Ahmed glaucoma valve 
surgery. [18]  
The exact mechanism by which corneal endothelial damage occurs is not well 
understood. One proposed hypothesis is that the proximity of the tube to the 
endothelium, by means of mechanical touch or fluidics from the tube, are a likely 
reason for endothelial loss.[19] However, an eye that requires a GDD is likely to have 
undergone numerous medical and surgical treatments before GDD implant surgery. 
As such, the corneal endothelium would have been already compromised. Therefore, 




The aim of this thesis is to study the effect of Molteno implant tube positioning on 
the corneal endothelium and determine any correlations. To our knowledge, this is 
the first comprehensive study of the chagnes in corneal endothelium following 









2.1 Anatomy and physiology of the cornea 
The human cornea is a unique structure. Optically, it makes most of the eye’s 
focusing (refractive) power, about twice as powerful as the natural crystalline lens. 
To achieve this, it must be transparent to permit the passage of light to the 
neurosensory retina with minimal reflection, aberration and distortion. The cornea is 
mechanically strong and resilient to withstand deformation of the globe and can 
resist significant blunt trauma. [20]  
The cornea forms the outermost, anterior, layer of the eyeball. The corneal diameter 
is smaller vertically (average of 10.6 mm) than horizontally (11.7 mm) and its average 
central radius of curvature is 7.8 mm with a flatter peripheral curvature due to an 
increased radius of curvature in the periphery. Corneal Thickness decreases from 
peripheral (average = 670 microns) to central (average = 535microns).[21-23] The 
cornea is organised in 5 different avascular layers which are (from anterior to 
posterior): Epithelium; Bowman’s layer; Stroma; Descemet’s membrane; and 
Endothelium layer (Figure 1). There are three main cell types in the cornea; epithelial 




2.1.1 Maintaining normal corneal integrity 
To achieve clear vision, the corneal epithelium needs to be smooth, the stroma must 
be transparent, and the endothelium must be functioning. The cornea is equipped 
with a maintenance system that will allow corneal epithelium renewal and wound 
healing. Being devoid of blood vessels, the corneal healing mechanism differs from 
that elsewhere in the body.[24] Maintenance of each corneal layer will be discussed 
below within its dedicated section in this chapter. However, it is important to 
highlight the importance of limbal epithelial stem cells (LESC). The limbus is 1.5-
Figure 1 (A) Diffuse illumination slit-lamp image of the human cornea and sclera. (B) Main 
anatomical components of the globe with detailed emphasis on the corneal and scleral components. 
(C) Slit-beam illumination slit-lamp image of the human cornea shows an optical section of the 
tissue. Notice the slight light scattering that occurs in the tissue, mainly from cellular 
components in cornea. (D) Histologic section of the human cornea labeling the five main cellular 
and extracellular matrix layers (toluidine blue ×25). Figure adopted from Adler’s Physiology of 
the Eye. (3) 
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2.0mm wide and it is where clear cornea transitions into an opaque scleral tissue. The 
sclera is not transparent because of the more random arrangement of collagen 
lamellae in the sclera compared with the highly organised corneal collagen lamellae. 
It is in this transition zone that the vascular conjunctiva also starts.[1] The limbus is 
an important anatomical and physiological landmark because it contains limbal 
epithelial stem cells, which have shown unique features such as longevity, high 
degree of renewal with a long cell cycle time, low proliferation error, and poor 
differentiation.[25] Moreover, LESCs have a higher proliferative activity than corneal 
epithelial stem cells. [26, 27] LESCs are circumferentially arranged at the limbal 
palisades of Vogt and the inter-palisade rete ridges as shown in figure 2. [28, 29] Loss 
of LESCs, for example secondary to severe alkaline chemical trauma or ocular 
inflammation (such in Stevens-Johnson syndrome), or in LESC deficiency (such as in 
aniridia), will significantly impair corneal epithelial homeostasis and recovery. [30] 
The trabecular meshwork (through which aqueous humour conventionally drains) is 
located at the limbus and it is where many immunological diseases originate from. 
At the limbus, high concentrations of immunocompetent cell types such as mast cells, 




2.2 Epithelial Layer 
The epithelial layer covers the surface of the cornea and it is bathed in tears. This 
layer is made of specialized stratified squamous epithelial cells stacked in 5-6 layers 
averaging 53 microns thick. These cells are non-keratinized and are highly 
proliferative. In other words, the corneal epithelium is always completely renewed 
every 7-10 days. The basal layer of the epithelium lays down a basement membrane 
that acts as a scaffold for epithelial cell movement and attachment.[1] Bowman’s 
layer is an acellular layer made of collagen and it resides between the basement 
membrane of the epithelial cells and the anterior stroma. This layer helps to maintain 
the shape of the cornea. [24, 31, 32] 
Epithelial cells are connected apically by a continuous band of zonula occludens tight 
junctions. This property gives the epithelium its barrier function that prevents 
A 
B 
Figure 2 Palisades of Vogt captured on slit lamp. A: radial line in inferior limbus in a 
fair-skinned patient. B: Radial lines shows pigmentation in a dark-skinned patient. 
Photos were adopted from Townsend, W.M., The limbal palisades of Vogt. 
Transactions of the American Ophthalmological Society, 1991. 89: p. 721-756. 
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transmission of ions and fluid into corneal stroma and protects against the 
penetration of pathogens.[33] 
Limbal and corneal epithelial cells live in a constant equilibrium between the 
differentiation of basal cells into superficial cells and the shedding of the outmost 
surface layer. This process occurs in a centripetal fashion as described by Thoft and 
Friend. This forms the basis of the XYZ hypothesis where X represents proliferation 
and stratification of limbal basal cells, Y centripetal migration of basal cells and Z 
desquamation of superficial cells. [34, 35]. In addition to the aforementioned 
characteristics of the corneal epithelium, extensive chemical and neural inputs are 
essential for epithelial renewal. Glycoproteins (fibronectin and hyaluronan)[36, 37], 
cytokines (epidermal growth factor, transforming growth factor-β – TGF-β, and 
interleukins)[38, 39], and an intact corneal sensation are all very important to 
maintain the integrity of the corneal epithelium.[40]  
 
2.3 Stroma 
The stroma forms almost 80-90% of the corneal thickness and is made of three major 
components, two acellular (collagen and proteoglycans) and one cellular 
(keratocytes). Together they ensure transparency, healthy functioning and repair of 
this layer. The stroma is reasonably permeable to facilitate diffusion of metabolites 
and fluid once they have passed through the barrier layers of the epithelium and 
endothelium.  
During repair of the stroma, keratocytes show fibroblastic healing properties with 
minimal proliferation. Therefore, unlike epithelial layer, the stroma cannot 
regenerate. Instead, scars form as part of stromal wound healing. Influx of fluid into 
the stroma (corneal oedema) causes disorganisation of stromal collagen fibrils, 
consequently, decreasing corneal clarity. Significant vision reduction occurs by scar 
tissue formation, corneal oedema, and when extensive lamellar or penetrating 




2.4 Endothelial Layer 
The endothelial layer consists of a single layer (about 4-6 microns thick) of 
hexagonally-shaped cells, derived from the neural crest during embryological 
development.[42] Endothelial cells continuously lay down a collagenous membrane 
forming a basement membrane, known as Descemet’s membrane. At birth, human 
corneas contain about 5000-7000 endothelial cells per mm2, but this number decreases 
to an average of about 2500-2700 cells/mm2 in older adults.[2, 43]  The endothelial cell  
loss occurs in the first 2 decades of life due to corneal growth and developmentally 
natural apoptosis. Endothelial cell density (ECD) continues to decline during adult 
life at a rate of 0.6% per year. [44, 45]. The human corneal endothelium has very 
limited innate, in vivo proliferative capacity, and so maintains its functions by 
continuous migration and expansion of cells to cover the space left by dead cells. 
This results in considerable change in the shape and size of endothelial cells. [46] 
Recently, some studies suggested that an adult stem cell population of corneal 
endothelial cells exists near Schwalbe’s line of the limbus, and proliferates in a 
limited fashion, particularly after injury. [47, 48] 
The aqueous humour is directly in contact with the endothelial layer which forms a 
gateway between the nutrients and ions in the aqueous humour and the stroma.[1] 
Diffusion of small molecules into the corneal stroma via the intracellular gaps 
between endothelial cells’ macula occludens tight junctions which are found on the 
lateral border of the cells. Endothelial cells have numerous cytoplasmic organelles, 
particularly mitochondria, and have thus been inferred to have the second highest 
aerobic metabolic rate of all the cells in the eye next to the retinal photoreceptors.[1] 
The primary function of the corneal endothelium is to maintain a state of relative 
dehydration of the cornea, hence, its transparency. This is achieved, as David 
Maurice[49] first described, through a dynamic process of a leaky barrier and a 
metabolic pump function. Since the cornea is devoid of blood- and lymph- vessels, 
transport of all essential nutrients via the endothelium is actively transported from 
the aqueous humour. To actively transport ions across the endothelium, two ion 
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transport systems are utilised. These are: the membrane-bound Na+ -K+-ATPase; and 
the intracellular carbonic anhydrase pathway. Both pathways produce a net flux of 
ions (Na+, K+, HCO3- and Cl-) resulting in an osmotic gradient forces water to move 
from the stroma into the aqueous humour.  
Corneal decompensation typically occurs when central corneal ECD reaches 
500cells/mm 2, which is a 90 percent decrease in central ECD from birth or an 80 
percent decrease from healthy adulthood levels. It is reassuring to see that there is 
plenty of cellular reserve remaining after an average human lifespan of 75–80 years 
of life. [46, 50] Corneal endothelial permeability does, however, gradually increase as 
central ECD decreases below 2000 cells/mm 2, but compensatory metabolic pump 
mechanisms, by increasing the rate of pumping or increasing the number of pumps 
in the endothelial cell membrane, keep the cornea at its normal dehydrated state 
until a central ECD of 500 cells/mm 2 is reached. At this low ECD, the permeability 
has increased to a point where the endothelial cells are overstretched and the 
metabolic pumps are overworked, failing to balance the leak of fluid from the 
aqueous into the stroma. Corneal oedema is the manifest result. [1, 51]  
Variations in endothelial cells shape and size are described as pleomorphism and 
polymegethism, respectively. It has been postulated that the most energy-efficient 
cell shape to cover a given area is a hexagon, and a normal cornea is expected to have 
60% of the endothelial cells as hexagons.[46] The perfect corneal endothelium should 
have no variation in individual cell area but, naturally, endothelial cells vary size and 
this is described by the coefficient of variation (CV) function. ECD is determined 
from the average cell area as follows: 
ECD = 106 / average cell area 
Where ECD = cells per mm2, average cell area μm2, and 106 is used to convert the 
units of measure. As the standard deviation of average cell area increases, the 
accuracy of estimating ECD is reduced. Therefore an increase in CV is caused either 
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by a decrease in mean cell area or by an increase in the standard deviation of the 
mean cell area, or both.  
CV is determined as follows: 
CV = SDcell area / mean cell area (μm2) 
Where SD is standard deviation of mean cell area.[52] 
2.4.1 Endothelial cell damage 
The most common stressors, besides infection and accidental trauma, to corneal 
endothelium are contact lens wear and intraocular surgeries. Contact lens wear 
causes reversible corneal oedema, and long-term use of contacts (although not a 
cause of loss of ECD) will lead to increase polymegethism and reduction in 
pleomorphism. This is believed to be the result of hypoxia induced by the low 
oxygen permeability of the contact lens. [53, 54] On the other hand, all intraocular 
surgeries cause immediate and, probably, chronic damage to corneal endothelium. 
One randomised controlled trial reported an average ECD loss of 10% by 12 months 
after cataract extraction. There was no significant difference between cataract 
extraction by phacoemulsification or extracapsular surgeries. [55] Out of all 
intraocular surgeries, corneal transplantation is associated with the greatest ECD 
loss. Longitudinal studies up to 20 years following penetrating keratoplasty, report 
an acute loss of over 38% of endothelial cells in the first year following surgery, and 
then a linear rate of 4.2-8.4% of ECD loss per year. [56] 
2.5 Specular microscopy  
Specular microscopy is used to, non-invasively, view and photograph the corneal 
endothelial cell layer, in vivo. The optical principle of all clinical specular 
microscopes relies on specular reflection properties of light. Light travels through the 
slit of the specular microscope and illuminates the cornea. As the light passes from a 
given medium to another, such as the corneal endothelium to the aqueous humour, 
some of the light is refracted, some gets absorbed and finally some is reflected. The 
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specular reflex occurs at corneal endothelium-aqueous humour interface. The 
interface must be regular and smooth-surfaced with the light from the subject having 
an angle of incidence equal to the angle of reflection to the observer or the camera. 
The amount of light reflected depends on the refractive indices of the media and the 
curvature of the reflecting surface. The larger the difference between the refractive 
indices, the more intense the reflectance that will occur at the interface. [52, 57] 
Projected light at the cornea passes through the epithelium and stroma before it 
reaches the endothelium. During its passage through the corneal layers, some of the 
light is scattered, and some is reflected differently at each layer of the cornea. It has 
been estimated that only 0.022% of the projected light is specularly reflected by the 
corneal endothelium.[58] A portion of the reflected and scattered light is collected by 
the objective lens of the photomicroscope, producing an image at the sensor or film 
plane. If the light beam is made wider, a larger field of endothelial cells is viewed. 
However, a wide beam illuminates more of the corneal tissue anterior to the 
endothelium. As a result, a greater amount of scattered light reaches the film plane, 
consequently, there is a loss of endothelial cellular definition. The presence of 
epithelial or stromal oedema as well as other corneal opacities increases the amount 
of light scattered back to the instrument and obscures the image of the underlying 
endothelium.[41] In the clear cornea, the resolution of the clinical specular 
microscope is sufficient to provide information on endothelial cell morphology.  
All currently used specular microscopes employ a computer interface to capture 
endothelial images and perform the necessary analysis of endothelial cell 
characteristics. Specular microscopes can be divided into two major models: Contact 
microscopes in which a coupling agent is used to directly couple with the cornea and 
flattens the curvature of the cornea leading to a larger image; Non-contact 
microscopes where endothelial images are acquired without touching the eye. The 
specular reflex area is smaller in non-contact microscopes because of the corneal 
curvature. The image acquired from a non-contact specular microscope will examine 
150-170 endothelial cells whereas a contact specular microscope is capable of 
examining 700-800 endothelial cells in a single image. [52, 59]  
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2.5.1 Normal endothelial cells characteristics  
During each examination using a specular microscope, endothelial cell morphology 
analysis is conducted and that includes cell area (µm2); endothelial cell density – 
ECD, (cell/mm2), polymegethism (coefficient of variation of area, CV); and 
pleomorphism (percentage of hexagonal cells). An average ECD for an adult is 2500-
2700 cells/mm2. A normal range for polymegethism ranges between 0.22 to 0.31 for 
an adult.[46] Increase in polymegethism may be one of the earliest signs of corneal 
disease with an increase in CV to 0.35-0.40. Any CV above 0.40 is considered 
abnormal.[60] In an ideal cornea, 100% of the endothelial cells are hexagonal, but a 








Glaucoma is an eye condition that encompasses a large group of similar diseases. 
These diseases essentially lead to optic neuropathy and consequently, in the long 
term, blindness.  According to the World Health Organisation (WHO), glaucoma is 
the second leading cause of blindness worldwide after cataracts. Unlike cataract, the 
damage from glaucoma is irreversible and, therefore, creates major public health 
concerns, especially in the developing world.[61] In 2013, it was estimated that over 
64 million people were affected by glaucoma and this figure is likely to increase to 
around 76 million next year (2020), and to over 111 million by 2040.[8, 62]  
There are certain clinical features found between different types of glaucoma. These 
features include optic disc cupping; characteristic visual field losses; and, 
occasionally, elevated intraocular pressure. The visual loss from most types of 
glaucoma is gradual and painless, which is why patients often present late in the 
course of the disease. [63] 
Glaucoma can be classified into two main types (according to the configuration of the 
irido-corneal angle): open-angle; and closed-angle glaucoma. Both types can present 
as a primary disease. Secondary glaucoma can present due to other causes such as 
trauma, prolonged corticosteroids use, uveitis, and neovascular processes, such as 






3.2 Pathophysiology  
Glaucoma pathogenesis is complicated and not fully understood, but retinal ganglion 
cell death is highly related to the level of intraocular pressure. Aqueous humour is 
secreted from the ciliary body continuously and drains out of the eye via two 
independent pathways—the trabecular meshwork and uveoscleral outflow pathway. 
The balance between secretion and drainage determines the intraocular pressure of 
the eye.[9] In patients with open-angle glaucoma, the trabecular meshwork exhibits 
increased resistance to aqueous outflow. In contrast, in eyes with angle-closure 
glaucoma there is a physical blockage to the drainage pathways, typically by the iris. 
[9, 64] (Figure 3). Intraocular pressure can cause mechanical stress and strain on the 
posterior structures of the eye, particularly the lamina cribrosa where the optic nerve 
fibres (retinal ganglion cell axons) exit the eye, because the lamina is considered the 
weakest point in the wall of the eye.[65, 66]. Consistent elevation in intraocular 
pressure induces stress and strain may result in an out-bulging force where 
deformation, and remodelling of the lamina cribrosa will occur accompanied with 
mechanical axonal damage and disruption of axonal transport.[9, 64, 67] High levels 
of energy demand may be difficult to meet during periods of intraocular pressure–
induced metabolic stress because of possible mitochondrial dysfunction in retinal 
ganglion cells and astrocytes.[1, 68] Impaired microcirculation, altered immunity, 
and oxidative stress may also cause glaucoma. Primary neural pathological 
Figure 3 Schematic representation of angle configuration in A: open-angle glaucoma and 




conditions may result in neurodegeneration of other retinal neurons and cells in the 
central visual pathway by altering their environment and increasing susceptibility to 
damage.[69] 
3.3 Glaucoma Treatment 
The treatment is aimed at halting the progression of  glaucomatous optic neuropathy. 
The only modifiable risk factor is intraocular pressure. Once the diagnosis is 
confirmed, topical treatment is usually very effective in controlling intraocular 
pressure.[70] The next step is to utilise advancements in technology, such as laser, to 
perform laser trabeculoplasty which is as effective as topical treatment.[71]  
Should the above fail to control glaucoma, surgical options will be the next step to 
prevent any damage to the sight. Trabeculectomy is the most commonly performed 
incisional surgical procedure to lower intraocular pressure.[9] It comprises of 
fashioning a conduit to drain aqueous humour from the anterior chamber into the 
sub Tenon’s space.  This is done by surgically excising a small portion of the 
trabecular meshwork and its adjacent corneoscleral tissue. Anti-scarring (anti-
fibrotic) agents are frequently applied to the surgical site to minimise the chance of 
postoperative fibrosis and failure.[72] Trabeculectomy is disliked for its relatively 
high early postoperative period complications, such as hypotony. [14] Glaucoma 
drainage devices that drain aqueous humour to an external, subTenon’s, reservoir is 
an alternative surgical option for eyes that have had a failed trabeculectomy or are 
thought to be at high risk of failure. Glaucoma drainage devices have been shown to 
be as effective, in lowering intraocular pressure, as trabeculectomy. [11] 
3.4 Historic perspective 
In 1907, Rollet implanted a horse-hair thread in an attempt to drain aqueous fluid out 
of the anterior chamber into the subconjunctival space at the limbus.[13] Many tried 
since then without mentionable success. These attempts included silk, gold, 
platinum, tantalum, glass rod, and polythene tubes. [13] Failures were attributed to 
excessive scar formation near the limbus, migration of the implant and conjunctival 
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break-down. [73] Molteno, in 1969, introduced the concept of the large surface area 
needed to disperse the aqueous. He inserted a short acrylic tube attached to a thin 
acrylic plate and sutured it to the sclera, adjacent to the limbus. Most of the surgeries 
failed within 3 to 6 months because of reasons  mentioned earlier. [74] In 1973, 
Molteno improved on the concept and decided to move the reservoir further 
posteriorly, away from the limbus. Then the rate of success became clinically 
meaningful.[75] All of the currently available glaucoma drainage devices are based 
on the concept of the Molteno implant (Molteno Ophthalmic Limited, Dunedin New 
Zealand), which has a long silicone tube attached to a large reservoir (plate) placed 
9–10 mm posterior to the limbus. The Molteno implant lacks a resistance mechanism 
to prevent immediate flow post-operatively. Potential early complications are 
hypotony, flat anterior chambers with tube-corneal touch, and choroidal 
effusions.[73] Two major concepts followed to modify glaucoma drainage devices. 
The first was the introduction of a valve to offer resistance to the aqueous outflow in 
the initial post-operative phase in an attempt to prevent the aforementioned 
complications. Theodore Krupin, in 1976, introduced Krupin slit valve (Hood 
Laboratories, Pembroke, MA) and Marteen Ahmed in 1993, introduced the Ahmed 
Glaucoma Valve (New World Medical, Rancho Cucamonga, CA). Both devices are 
pressure-sensitive, unidirectional valves that provide resistance to the flow of 
aqueous.[13] The second modification was increasing the surface area of the end-
plate, providing lower intraocular pressures. Molteno, in 1981, called it “the optimal 
design of drainage implants for glaucoma”  and introduced the double-plate 
implant.[76]  
George Baerveldt, in 1992, introduced Baerveldt glaucoma implant (Johnson and 
Johnson, Santa Ana, CA), a non-valved silicone tube attached to a large barium-
impregnated silicone plate.[13]  
In order to overcome the problem of early hypotony, Molteno proposed placing an 
absorbable tie (5-0 polyglactin sutures) around the silicone tube, near its insertion on 
the end plate.[77] These devices are made of different biomaterials: the Molteno is 
made of polypropylene whereas Ahmed valves, the Krupin and the Baerveldt are 
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made of silicone. One study compared the propensity for these biomaterials to 
induce inflammation. They reported increased inflammation and fibrosis with 
polypropylene compared to silicone. [78]  Studies are yet to test these differences in 
clinical settings regarding the risk of bleb scarring and subsequently failure.  
With the increasing use of the glaucoma drainage devices,[10] it is 
important for physicians to be aware of the differences and features that come with 
each device to enable them to select the appropriate device for a given case. 






4.1 Current understanding: Relationship between glaucoma drainage devices and 
the corneal endothelium 
Corneal complications are reported after glaucoma surgery with higher incidence 
following glaucoma drainage device (GDD) implantation. [12, 14] Patients 
undergoing GDD, usually suffer from refractory glaucoma and may have already 
undergone one or more intraocular surgeries, consequently, they may present with 
some degree of compromised cornea.[79]  Glaucoma surgical techniques have 
improved with regard to the careful use of anti-fibrotic agents and the development 
of biocompatible  GDD plates and tubes, which reduces fibrosis and increases the 
chances of success. [80] The negative effect of the GDD on the corneal endothelium 
has been documented with varying severity, regardless of the type of GDD. [15] 
There are number of proposed hypotheses for the mechanism of endothelial cell loss 
following GDD implantation.  
Intraocular inflammation, and its sequelae with formation of peripheral anterior 
synechiae (PAS), was reported to increase ECD loss. Hau et al. examined the corneal 
endothelium in eyes with Ahmed valve implants, and they reported lower ECD 
counts in eyes that had PAS. [81] PAS is likely to damage corneal endothelium by 
mechanical disturbance of the tissue. Intraocular inflammation was documented to 
affect the endothelium by disrupting Na+ -K+ - ATPase pump and compromising 
endothelial barriers, resulting in corneal oedema.[82]  
An experiment was done on bovine corneal endothelium to observe  the degree of 
damage caused by materials found in modern GDD. Silicon was found to be less 
harmful than polymethylmethacrylate (PMMA). [83] This indicates that the 
biomaterials used in GDD may influence ECD loss.  
Anti-fibrotic agents were also postulated to cause more ECD loss but not enough 
literature is available to support this theory. [84] Another hypothesis is that the 
aqueous humour composition is altered after GDD surgery due to exposure to the 
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sub-Tenons’s space. This may alter the milieu surrounding the endothelial cells. [85] 
It has been found that aqueous humour components in glaucoma eyes differ from 
normal eyes. One component that was measured is the total protein concentration. It 
was found that total protein concentration in the aqueous humour in glaucomatous 
eyes was two times higher than normal eyes.[86] Moreover, collagen synthesis in the 
aqueous humour increases as a result of postoperative inflammation.  The activity of 
collagen synthesis in the aqueous humour in eye after glaucoma surgery was 20-fold 
higher than controls (eyes with no prior eye surgery). Three eyes with Molteno 
implants showed 12-fold increase in collagen synthesis activity compared to 
controls.[85]  However, there is no study that has examined the aqueous before and 
after inserting GDDs.  
The proximity of the tube, in the anterior chamber, to the corneal endothelium is 
probably the most obvious theory to explain the harmful effects of the tube. A few 
studies found that the farther the tube from the cornea the less ECD loss observed. 
[16] The fluidics and turbulence at the tip of the GDD tube is also another proposed 
mechanism of focal loss of endothelial cells. [17, 87] During GDD insertion, a 
superior corneal traction (stay) suture is usually employed to provide adequate 
exposure to the surgical site. Therefore, some studies attributed the observed 
superior loss to the placement of the suture. [16, 17] 
During the initial phase post GDD insertion, high IOP is sometimes managed 
medically with topical drops and/or orally. In addition, some surgeons apply an 
ocular massage, which may cause intermittent tube–corneal touch, leading to 
increased endothelial cell loss.[19]  
A case series of 3 patients noted tube movement within the anterior chamber in 
different directions of gaze. Another noted that Ahmed valve tubes had shortened 
over a 12-month period after surgery[88], and another confirmed its stability.[89] A 
Baerveldt glaucoma implant was found to have had moved significantly closer the 
corneal endothelium when placed freely in the anterior chamber as opposed to when 
implanted transiridially.  [90] Nevertheless, movement of the tube in the anterior 
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chamber is another possible explanation by which corneal endothelium damage 
occurs.  
Several of the aforementioned studies used non-contact anterior segment ocular 
coherence tomography (AS-OCT) to visualise the tube in the anterior chamber. AS-
OCT has been shown to provide valuable qualitative and quantitative information of 
the eye’s anterior segment structure.  
 
4.2 Anterior-segment OCT 
The OCT utilises light waves of different wavelengths and their produced 
interference patterns to obtain and construct an image. A near-infrared light beam 
(800 nm) is split by a beam splitter, using a Michelson interferometer, into two 
beams. The first (the reference beam) is aimed at moveable mirror, and the second 
beam is aimed the tissue of interest. The mirror is adjusted to allow an interference 
pattern to occur only when both beams have travelled for the same amount of time.  
The strength of each reflected signal corresponds to the depth observed in each scan. 
A wavelength of 800nm has a limited tissue penetration capability and will not 
produce a good quality anterior segment image. Therefore, a super-luminescent 
diode with a wavelength of 1310nm, which allows better penetration of tissue,  
(hence, a higher quality image acquisition) is employed. [91, 92] 
This technology allows us to visualise the cornea, the anterior chamber angle, iris and 




Glaucoma drainage devices (GDD) are now being  utilised in recalcitrant glaucoma 
more commonly than  in the past. One unique ongoing issue with the use of GDD is 
progressive damage to the corneal endothelium. The most common devices that are 
currently used are the Ahmed Glaucoma Valve, the Baerveldt Glaucoma Implant, 
and the Molteno Glaucoma Implant. There is ample research describing the changes 
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in corneal endothelium following Ahmed and Baerveldt device’s insertion. The 
literature is lacking when it comes to discussing the Molteno implant and its effect on 
the corneal endothelium. The aim of this study, to the author’s  knowledge, the 
largest retrospective case-control cohort of patients with Molteno implants, is to 





5.1 Eligibility and patient recruitment 
All patients were recruited from the Otago Glaucoma Surgery Outcomes Follow-up 
Study (for which they had already provided prior written consent), between 
November 2013 and November 2014. Ethical approval, from the University of Otago 
Ethics Committee, was obtained (Appendix 1) to collect data from patients attending 
their regular appointment at the Eye Department, Dunedin Public Hospital. 
Attending ophthalmologists and ophthalmology registrars were aware of the study 
and were asked to contact the study co-ordinator (Dr Ammar Bin Sadiq), when a 
patient with a Molteno implant had attended their clinic appointment. All patients 
had undergone successful Molteno implant surgery for non-traumatic glaucoma. 
Clinical cornea clarity was mandatory for enrolment in order to facilitate specular 
microscopy. In cases of bilateral Molteno implants, both eyes were enrolled as cases. 
If the other eye of the subject was glaucomatous but did not have an implant, it was 
used as a control eye and underwent the same tests. Patients with traumatic 
glaucoma, congenital glaucoma, irido-corneal endothelial (ICE) syndrome and 
corneal disease, including corneal grafts were excluded from the study. 
Agreeing to participate was entirely voluntary and withdrawal was voluntary. No 
further written consent was required but recruited patients were made aware of the 
study and the nature of the additional tests. Verbal consent was obtained from all 
patients. Written information was provided (Appendix 2) and any further questions 
were addressed by the study coordinator. All approached patients agreed to 
participate and undergo additional tests. Demographic (age and sex) and clinical 
information (diagnoses, intraocular pressure –  IOP, time since Molteno implant 
surgery, any previous intraocular surgeries) was collected for all enrolled patients 
from the medical notes. Follow up appointments and modification of treatment, if 
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required, was left at the treating doctor’s discretion. A Microsoft Excel spreadsheet 
was used to store all the raw data on a Dunedin Hospital computer with a unique 
identifier code for each patient. Patient’s personal information was stored on an  
Otago Glaucoma Surgery Outcome Study Follow-up Study computer, on-site at the 
Eye Department, Dunedin Public Hospital.   
5.2 Investigation and outcome measures 
After confirming eligibility, patients underwent two clinic-based tests that were 
performed by the investigator (Dr Ammar Bin Sadiq). The first was a qualitative 
assessment of their corneal endothelium using non-contact specular microscope 
(Nidek® CEM-530, NIDEK Co., Ltd. Japan). The central (1 point at 0°) and peripheral 
(4 points at 27° from the visual axis) areas, representing the superio-nasal, superio-
temporal, inferio-temporal and inferio-nasal aspects of the cornea were examined. 
Specular microscopy was used to record the following parameters: central 
endothelial cell density (cECD) described in cells/mm2, peripheral endothelial cell 
density in four corneal quadrants (superior-nasal (SNECD), superior-temporal 
(STECD), inferior-nasal (INECD) and inferior-temporal (ITECD)), endothelial 
pleomorphism as a percentage of hexagonal endothelial cells (HEX), endothelial 
polymegethism represented by coefficient of variation of the average cell area (CV) 
as well as corneal thickness (CT) in microns. Figure 4 illustrates the measured corneal 
locations. This is achieved by using Nidek specular microscope fixation target lights 
(as in figure 5). In order to examine the superio-nasal cornea the lower outer light 
will operate to bring the area of interest into view, and so on for the other corneal 
areas. Specular microscopy was repeated at three monthly intervals and results from 
corresponding corneal areas were compared between study eyes (cases), and control 
eyes (controls). Changes over time in all corneal parameters were also documented. 
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Specular microscopy of at least 40 cells per field of view were required for inclusion. 
[60]  
The second test was performed using non-contact anterior segment optical coherence 
tomography (AS-OCT) (TOPCON® 2000, Topcon corporation, Japan) to assess the 
position of the Molteno® implant tube in the anterior chamber. Tube-related 
parameters were measured manually on the acquired scans as illustrated in figure 6. 
These parameters were: tube length (TL) in millimetres, corneal-tube angle (CTA) in 
angular degrees and corneal-tube distance (CTD) in millimetres.   
 Figure 4 Measured corneal locations 
Figure 5 Fixation targets on Nidek CEM-500 specular 
microscope. Figure is adopted from NIDEK. "Specular 





5.3 Statistical Analysis 
Descriptive statistics were used for demographic, clinical data and tube parameters. 
Normality of data was confirmed by Shapiro-Wilk Test (p ≥ 0.05) and plotting 
histograms. Between-group comparisons of the continuous variables (e.g. IOP, ECD, 
CV, Hex and CT) were performed using the independent t-test. When normality was 
not satisfied, comparisons were performed using the nonparametric  Mann Whitney 
U test. Wilcoxon signed-rank test was used to evaluate within group differences over 
time. The significance of the Pearson correlation coefficient (when the data was 
parametric) or the Spearman correlation coefficient (non-parametric) was used to 
assess the correlation between each pair of continuous variables. To explain the 
factors independently associated with corneal endothelial parameters, multiple 
regression analysis of selected variables. Statistical significance for all comparisons 
was set at a P value of less than 0.05. Statistical tests were performed using IBM 








Figure 6 Example of acquired image of Molteno tube in anterior chamber using Topcon AS-OCT. 





6.1 Demographics and Clinical details 
Forty-four patients agreed to participate in this study at baseline. Of the 44 patients, 
some had a Molteno implant in only one eye (unilateral) and some had an implant in 
both eyes (bilateral). Twelve patients were excluded because they did not attend all 
three visits, three were excluded because the tubes were not visualised in the anterior 
chamber using AS-OCT,  two were excluded due to poor quality specular 
microscopy measures and one patient died during the study period. We were left 
with twenty-six (26) patients – 35 eyes – who had complete data sets. Nine patients 
had bilateral Molteno implants. Figure 7 summarises the recruitment process.  Fellow 
eyes that did not have a Molteno implant acted as controls (17 eyes).  
 
Twenty-two eyes were recruited as controls. The contralateral eye for one included 
patient with Molteno implant, was not included as a control due a previous 
Gundersen conjunctival flap. Three control eyes were excluded due poor specular 
microscopy measures. This brought the total number of control eyes to 18 eyes - 18 






Total number of 
participated patients:  
44 patients 
12 patients did not 




One (1) patient died 
Final study sample:  
26 patients (35 eyes)  
Poor corneal 
measurements in two 
(2) patients  
Tube was not 
visualised in three (3) 
patients 
Figure 7 Excluded participants 
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In eyes with a Molteno implant, the mean ± SD age was 71 ± 11 years. This group 
included 22 males and 13 females. There were 19 right eyes and 16 left eyes. The 
majority of eyes with implants (54%) suffered from primary open angle glaucoma 
(POAG), followed by pseudo exfoliation glaucoma (PXF) – 20%, and equal number of 
patients with uveitic glaucoma (UG), neovascular glaucoma (NVG) and chronic 
angle closure glaucoma (CACG) with under 9% in each group. This is summarised in 
figure 8.  
 
The average time between the Molteno implant surgery and the first (baseline) exam 
for this study was 6.6±5.1 years. Mean pre-Molteno implant insertion IOP was 
35.4±11.3mmHg. Fifty-one percent (51%) of eyes with Molteno drains had undergone 
other intraocular surgeries, either prior to or after Molteno implant surgery. These 
surgeries included cataract extraction, trabeculectomy, or both. None of the included 















Figure 8 Glaucoma Diagnoses in Molteno implant group. (POAG = primary open angle glaucoma, PXF = pseudo-
exfoliation glaucoma, UV= uveitic glaucoma, NVG = neovascular glaucoma, CACG = chronic angle closure glaucoma. 
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In the control group (n=18), the mean age was 75±10 years. This group included 7 
men and 11 women. There was an equal number of right and left eyes. Most of the 
control group suffered from POAG, 39%, followed by PXF at 28%, UG at 17%, NVG 
at 11% and only 1 eye presented with chronic angle closure glaucoma (CACG). This 




The mean pre-glaucoma treatment IOP was 21.0 ± 6.6mmHg. Fifty-six percent (56%) 
of eyes in this group had undergone prior intraocular surgeries 
There was no statistically significant difference in age, sex, glaucoma diagnosis or 
other intraocular operations between controls and eyes with Molteno implants. The 
latter group had a significantly higher mean pre-implant IOP than that for the control 
group (35.4±11.3 vs 21.6±6.6mmHg, p value <0.001). Table 1 provides a summary of 














Figure 9 Glaucoma Diagnoses in control group. POAG = primary open angle glaucoma, PXF = pseudo-exfoliation 
glaucoma, UV= uveitic glaucoma, NVG = neovascular glaucoma, CACG = chronic angle closure glaucoma. 
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Table 1: Demographics and Clinical Details 
 Cases Controls p value 
Number 35 eyes 18 eyes  
Age 71±11 75±10 0.34 
Sex 
M N=22 M N=7 
0.10 
F N=13 F N=11 
Laterality 
Right N=19 Right N=9 
 
Left N=16 Left N=9 
Glaucoma diagnosis 
POAG 54% POAG 39% 
0.56 
PXF 20% PXF 28% 
NVG 9% NVG 17% 
UV 9% UV 11% 
CACG 9% CACG 6% 
Pre-treatment IOP* 35.4±11.3 mmHg 21.6±6.6mmHg <0.00 
Prior surgeries 18 (51%) 10 (56%) 0.78 





Table 1 POAG = primary open angle glaucoma, PXF = pseudo-exfoliation glaucoma, UV= uveitic glaucoma, 
NVG = neovascular glaucoma, CACG = chronic angle closure glaucoma. IOP= intraocular pressure. SN= 
superio-nasal. ST= superio-temporal. Pre-treatment IOP: for cases indicated pre-implant insertion and for 
controls indicates pre-glaucoma treatment. Level of significance p value ≤ 0.05. 
 
6.2 Corneal parameters 
Corneal parameters were completed in all cases for the central location. However, 
measurements in peripheral locations were not always possible or were of adequate 
quality. Complete data was obtained for 26 eyes (out of 35 eyes) for SN location and 
32 eyes in ST, IT and IN locations. For the control group, data was complete in all 
corneal locations. 
At baseline, the control group (n=18) had a mean (±standard deviation (SD)) central 
ECD of 1968±474 cells/mm2. By comparison, Molteno implant eyes (n=35) were 
associated with a numerically smaller mean central ECD of 1788±526 cells/mm2. 
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There was no statistically significant difference between the means in central ECD 
between the two groups, p = 0.22. At 3 months, control eyes had higher central ECD 
count than cases but remained statistically insignificant. However, at 6 months, there 
was a statistically significant difference between the means of the two groups, p = 
0.018. Thus, at the final follow up, mean central ECD in Molteno implant eyes, 
1657±537 cells/mm2, was statistically lower than mean central ECD of the control 
group, 2018±454 cells/mm2.  
The control group had a mean SN ECD of 2185±500 cells/mm2,2134±622 cells/mm2 
and 2184±499 cells/mm2 at baseline, 3 months and 6 months visits, respectively. Eyes 
with Molteno implants had much lower SN ECD at baseline: 1855±133 cells/mm2, at 3 
months: 1641±140 cells/mm2 and at 6 months: 1609±89 cells/mm2. Although cases had 
much lower SN ECD counts the difference (between cases and controls) was only 
statistically significant at 6 months, p < 0.0001. The control group had a mean ST ECD 
of 2315±516  cells/mm2, 2176±562 cells/mm2 and 2218±492 cells/mm2 at baseline, 3 months 
and 6 months visits, respectively. Eyes with Molteno implants had much lower ST 
ECD at baseline: 1865± 464 cells/mm2, at 3 months: 1806±558 cells/mm2 and at 6 months: 
1843± 594 cells/mm2. Cases had much lower ST ECD counts than controls, which was 
only statistically significant at 6 months, p < 0.01. A statistically significant difference 
between the two group’s mean IN ECD was also observed at the final visit. Cases 
had lower IN ECD counts, 1878±473 cells/mm2  compared to controls,2366±431 cells/mm2 
.  Cases had a numerically lower IT ECD, 1853± 462 than controls, 2081±409 but this did not 
yield a statistically significant result The reader is referred to tables 2 and 3 for the actual 
ECD counts.  
Over the course of the six-month period for the control group, the observed changes 
in all corneal parameters, in all locations, was not statistically significant. For 
example, mean central ECD, in control eyes, did not change significantly between 
time points, p = 0.42.  
Whereas in eyes with Molteno implants, a significant effect of time on central ECD 
was observed when comparing central ECD at baseline (1788±526 cells/mm2) to six 
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months (1657±537 cells/mm2); p = 0.004, and when comparing baseline to 3 months 
(1729±537 cells/mm2); p = 0.03. There was no significant change between 3 months 
and 6 months (p=0.08).  
A similar pattern of results was observed in mean SN ECD over the 6 months period. 
Significant change in SN ECD was only observed between baseline (1838±811 
cells/mm2) and 6 months (1489±cells/mm2); p = 0.03, and from 3 months 
(1641±575cells/mm2) and 6 months; p = 0.02. No significant change in mean SN ECD 
from baseline to 3 months; p = 0.37.  
No other significant results were obtained for between group or within group 
comparison regarding other corneal parameters (CV, HEX and CT) across all corneal 
locations. 
Table 2 and 3 summarise mean ± SD for corneal parameters in the controls and cases 
groups, respectively. Statistically significant results were identified within the tables. 
Figures 10 and 11 help in visualising the change in corneal parameters over time in 
both cases and controls.  
Table 4 shows a summary of means of the difference between 6 months and baseline 
and the means for relative change (%) in ECD across corneal locations. The change in 
central ECD over the 6-month period in eyes with Molteno implants had a mean of 
131.7±261.5 cells/mm2, which represents a relative loss of 7.2±15.5%. This is 
statistically higher than the mean change observed in central ECD for controls, 
49.9±164.4 cells/mm2, p = 0.008, which represents no measurable ECD loss. There was 
no other statistically significant result in any of the documented changes in ECD, CV, 
HEX, CT, across corneal locations, between cases and controls during the 6-month-





Table 2 Summary of means and standard deviations of corneal parameters in control group 
Corneal 
Location 
Corneal Parameter Baseline ± SD 3months±SD 6months±SD 
Central 
ECD (cells/mm2) 1968±474 2014±465 2018±454** 
ECD Change % - 2.3% 3.2% 
CV 29±9 32±14 31±11 
CV Change % - 10.3% 6.9% 
HEX % 67±9 69±6 73±7 
HEX Change % - 3.0% 9.0% 
CT µm 516±31 517±32 521±33 
CT Change %  0.2% 1% 
N 18 16 18 
Superio-
nasal 
ECD (cells/mm2) 2185±501 2134±622  2185±499**  
ECD Change % - -2.3% 0.4% 
CV 32±11 26±10 32±13 
CV Change %  -17.1% 1.9% 
HEX % 73±7 69±14 71±12 
Hx Change % - -5.8% -2.9% 
CT µm 563±54 576±45 577±56 
CT Change %  2.3% 2.4% 








ECD (cells/mm2) 2315±516  β β 2176±562 2218±492 β β 
ECD Change % - -6.0% -3.1% 
CV 33±12 37±15 34±11 
CV Change % 0 12.2% 2.1% 
HEX % 69±10 61±6 67 ± 9 
Hx Change % - -11.1% -3.3% 
CT µm 545±37 551±41 548±35 
CT Change % - 1.0% 0.6% 
N 18 14 18 
Inferio-
temporal   
ECD (cells/mm2) 2176±364 2202±452 2081±409 
ECD Change % - 1.2% -1.0% 
CV 35±14 32±13 36±21 































HEX % 69±6 67 ± 8 66 ±11 
Hx Change % - -2.3% -3.8% 
CT µm 519±40 526±37 526 ±36 
CT Change % - 0.41% 1.0% 
N 18 16 18 
Inferio-
nasal 
ECD (cells/mm2) 2270± 555 2459±528 2366±431 β β 
ECD Change % - 8.3% 7.5% 
CV 33±16 34±13 31±13 
CV Change % - 5.5% -3.6% 
HEX % 66±12 63±12 61± 14 
Hx Change% - -5.7% -8.6% 
CT µm 547±37 549±61 549±40 
CT Change % - 0.4% 0.5% 
N 18 16 18 
SD: Standard deviation. ECD: endothelial cell density. CV: coefficient of variation. HEX: 
pleomorphism. CT: corneal thickness. ** Between group Independent t test, p value= <0.01 
β βBetween group Mann Whitney U test, p value = <0.01 
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Table3: Summary of means and standard deviations of corneal parameters in Molteno implant group 
Corneal 
Location 
Corneal Parameter Baseline (SD) 3months (SD) 6months (SD) 
Central 
ECD (cells/mm2) 1788±526¥ 1729± 633  1657±537**¥ 
ECD Change % - -3.3% -7.4% 
CV 34±14 33±13 31±12 
CV Change % - -2.9% -8.8% 
HEX % 69±12 70±12 68±10 
HEX Change % - 1.4% -1.4% 
CT µm 538±39 535±43 537±44 
CT Change % - -0.6% -0.2% 
N 38 33 38 
Superior-
nasal 
ECD (cells/mm2) 1855±668¥ 1641± 575¥ 1609± 454¥** 
ECD Change % - -11.5% -6.9% 
CV 35±16 36±17 31±12 
CV Change % - 2.9% -11.4% 
HEX % 70±11 69±5 63±18 
Hx Change % 0 -1.4% -10.0% 
CT µm 572±50 553± 65  581± 65 
CT Change % - -3.3% 1.6% 
N 26 18 26 
Superior-
temporal  
ECD (cells/mm2) 1865± 464 1811±558 1843± 594 β β 
ECD Change % - -2.9% -1.4% 
CV 37±16 32± 12 36± 16 
CV Change % - -13.5% -2.7% 
HEX % 65±10 70±12 67±16 
Hx Change % - 7.7% 3.1% 
CT µm 562±44 558±53 549±45 
CT Change % - -0.7% -2.3% 




ECD (cells/mm2) 1925± 469 1877± 469 1853± 462 
ECD Change % - -0.7% -2.4% 
CV 33±8 36±17 30±11 






HEX % 65±11 68±11 66±10 
Hx Change % - 4.6% 1.5% 
CT µm 540±45 521±40 544±40 
CT Change % - -3.5% 0.7% 
N 32 24 32 
Inferior-
nasal 
ECD (cells/mm2) 1927± 546 1945±380 1878±473 β β 
ECD Change - 0.9% -0.5% 
CV 34±12 39±18 32±12 
CV Change % - 14.7% -5.9% 
HEX % 66±9 70±13 66±9 
Hx Change % - 6.1% 0% 
CT µm 556±57 545±56 567±43 
CT Change % - -2.0% 2.0% 
N 32 20 32 
SD: Standard deviation. ECD: endothelial cell density. CV: coefficient of variation. HEX: pleomorphism. CT: 
corneal thickness. ** Between group Independent t test, p value= <0.01. 
 β βBetween group Mann Whitney U test, p value = <0.01. 

























cECD SN ECD ST ECD IT ECD IN ECD
Molteno implant eyes - Endothelial cell density accross corneal locations over time
Baseline 3months 6months


































Control eyes - Endothelial cell density across corneal locations over time
Baseline 3months 6months




Table 4: Mean of change and mean of relative change in ECD from baseline to 6months across corneal 
locations between controls and cases 





















Central 49.9±164.4 +3.2±9.5 -131.7±261.5 -7.2±15.5 0.008 0.008 
SN -0.2±219.9 0.4±11.9 -246.2±549.3 -6.9±26.1 0.07 0.10 
ST -96.9±321.2 -3.1±12.2 -21.8±368.1 -1.5±20.6 0.87 0.67 
IT -94.8±234.8 -4.1±13.2% -70.9±262.7 -2.4±16.3 0.49 0.61 
IN 96.8±510.3 +7.5±24.2 -49.7±427.3 -0.5±20.8 0.49 0.64 
SD: standard deviation. SN: Superio-nasal ST: Superio-temporal IT: Inferio-temporal IN: Inferio-nasal. *Non-
parametric between group Mann Whitney U test; p value of significance is <0.05. Minus (-) sign indicates loss 
and Plus sign (+)  indicates increase.  
6.3 Tube parameters 
The Molteno Implant surgeries in this study were performed by 13 different 
glaucoma surgeons, all of whom had worked at Dunedin Public Hospital. The 
majority, 37%, of surgeries were performed by one surgeon. The most common 
observation on AS_OCT was that almost all tubes were placed posteriorly near and 
parallel to the iris plane. Twenty-five tubes were placed in the superior-nasal (SN) 
quadrant and 10 were placed superior-temporally (ST). The mean tube length (TL) 
was 2.8±0.9mm (range: 1.2 – 5.1mm), mean tube-cornea distance (TCD) was 
0.9±0.4mm (range: 0.2 – 2.1mm) and the tube-cornea angle (TCA) was 26.8±5.9° 
(range: 17.0 – 42.6°).  
A univariate regression analysis (F (8, 17) = 3.239, p = 0.020), R2 = 0.604, adjusted R2 = 
0.417) for eyes with Molteno implants showed that the SN ECD relative loss (%) over 
6 months was significantly associated with TL (β = 0.690; p = 0.019) and TCA (β = -
0.637; p = 0.004). SN ECD loss was also associated with type of glaucoma, particularly 
chronic angle closure glaucoma (β= -0.421; p = 0.031).  
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Table 5 shows results of the regression analyses of clinical variables and tube 
parameters associated with superio-nasal ECD loss. Relative change in corneal 
parameters (ECD, CV, HEX and CT) across other corneal areas (central, ST, IT and 
IN) was not associated with any of the tube parameters (TL, TCA and TCD).  
Relative change in corneal parameters (ECD, CV, HEX and CT) across other corneal 
areas (central, ST, IT and IN) was not associated with any of the clinical variables, 
namely, age, history of previous ocular surgeries, time since Molteno implant 
insertion or IOP. (all p values = >0.100).  
 
Table 5 Results of univariate regression analyses of clinical variable and tube parameters associated 
with superio-nasal ECD loss 
 β 95% CI p Value 
Age 0.471 -0.043 to 0.951 0.071 
Other intraocular surgeries -0.136 -0.509 to 0.239 0.457 
High IOP 0.205 -0.325 to 0.795 0.388 
Time since Molteno implant surgery 0.113 -0.375 to 0.600 0.634 
Glaucoma diagnosis (all) -0.615 -1.116 to -0.156 0.012 
CACG -0.412 -0.768 to -0.040 0.031 
TL 0.690 0.123 to 1.202 0.019 
TCA -0.637 -1.070 to -0.243 0.004 
TCD -0.392 -0.753 to 0.041 0.076 
Β: Beta coefficient.CI: confidence interval. IOP: intraocular pressure. CACG: chronic angle closure glaucoma. 






Discussion and Conclusion 
8.1 Discussion  
The primary aim of this study was to assess the effect of the Molteno Implant tube 
position in the anterior chamber on the corneal endothelium. It is widely known that 
having a glaucoma drainage device with the tube placed in the anterior chamber is 
detrimental to the corneal endothelium and increases the risk of corneal 
decompensation. The exact pathophysiology and mechanism by which corneal 
endothelial damage occurs, is still not clear.[11, 94] This study is the largest to 
investigate the relationship between the Molteno Implant tube and changes in the 
corneal endothelium.  
The latest model of the Molteno implant was introduced in 1976 as the first modern 
glaucoma drainage device to effectively control intraocular pressure in refractory 
glaucoma or in cases of previously failed filtration surgery.[75] After the emergence 
of t5 year results of the Tube Versus Trabeculectomy (TVT) study[11], which showed 
that tube shunt surgery has a higher success rate and lower re-operation rates than 
trabeculectomy, glaucoma surgeons have been utilising glaucoma drainage devices 
more often than before even in low risk cases.[10, 95] The TVT study described a 
relatively unique complication to tubes: a higher rate of corneal complications such 
as persistent corneal oedema (16% compared to 9% in the trabeculectomy group) 
with six tube patients needing penetrating keratoplasty. [14] Corneal complications 
were reported to be as high as 30% following Baerveldt implants [12], and 27% 
following Ahmed glaucoma valves implants [96], making corneal decompensation 
one of the most frequent complications after glaucoma drainage surgery.[13]  
There is a paucity of studies that reported on corneal complication after Molteno 
implant insertion. In one review, corneal decompensation developed in 50% of 
patients after 21 months post-Molteno tube implantation. [97] McDermott et al, 
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observed corneal endothelial densities in 19 eyes that underwent Molteno Implant 
insertion and concluded that there was no clinically significant cell loss.[87] They 
were the first to quantify an average loss of endothelial cells at a rate of two cells per 
square millimetre per postoperative month after an uneventful insertion of a Molteno 
Implant. A report from the Otago Glaucoma Surgery Outcome Study (OGSOS), by 
Molteno et al., reported five patients with Molteno Implants that underwent 
penetrating keratoplasty. However, four of those patients had corneal 
decompensation secondary to pre-existing risk factors or complications unrelated to 
implant insertion.[98] The cohort for this study, which  was  derived from the 
OGSOS, had a mean time since Molteno Implant insertion of more than 6 years (55% 
were 6 years or more post-surgery). There were no cases of persistent corneal 
oedema during our study. Nonetheless, two patients were excluded from our study 
due to a significant low cell count that precluded an accurate specular microscopy 
assessment. Such patients may be at risk of corneal oedema and/or decompensation. 
However due to the low number of excluded patients, the overall results were 
unlikely to be affected by if they were included. Our last measured central ECD 
differed significantly between the two groups. This suggests that there  was an ECD 
loss at slow rate that was not evident over three months but rather over a six month 
period.  
For our cases, the relative ECD loss over 6 months was 7.2% in the central and 6.9% 
in superior-nasal cornea. These figures are comparable with those of Mendrinos et al, 
who reported a loss of 7.9% and 7.5% in central and peripheral corneal ECD in eyes 
with Ahmed valve implants over a 6-month-period. [89] Nassiri et al. compared 
central ECD between the Molteno Implant and Ahmed valve implants after 24 
months. They did not examine the peripheral cornea or tube parameters. They 
reported a 12.37% (Molteno) and 11.52% (Ahmed) loss of central ECD, and 3.75% 
(Molteno) and 2.48% (Ahmed) increase in CV. There was no statistical difference 
between the two groups. [15] We did not observe any significant changes in ECD, at 
other corneal locations, of CV, HEX or CT within or between our cases and controls.   
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We reported more loss in the superio-nasal location compared to controls. It is 
important to note that about 71% of our cases had the Molteno Implant tube placed 
superio-nasally. The actual ECD count at six months was significantly lower in the 
superio-nasal area in eyes with Molteno Implant ,1609±454 cells/mm2, compared to 
controls, 2185±499 cells/mm2 (p value= <0.0001) but this significance did not translate 
into a statistically significant relative ECD change (-6.9% vs +0.4% in cases vs 
controls, p value = 0.2). This is likely due to the presence of large variation in results 
(standard deviation) in both groups.  
Kim et al., once again, observed a significant ECD loss in Ahmed valve compared to 
controls but that significance disappeared at 2 years.[18] This may indicate that there 
is a large degree of ECD loss in the first 2 postoperative years and then the decrease 
may continue at a slower rate.  
The EX-PRESS glaucoma drainage device (Alcon Laboratories, Fort Worth, TX, USA) has 
been also approved to treat glaucoma in 2002.[99] This device differs from 
aforementioned GDD, as EX-PRESS is made from stainless steel. EX-PRESS is also 
minute, non-valved and lacks a drainage reservoir when compared to other 
GDD.[100] Nonetheless, the presence of  this device in the anterior chamber has been 
reported to have an impact on the corneal endothelium. Ishida et al, reported 
endothelial cell loss of 4.4% at 24 months post EX-PRESS insertion. The EX-PRESS 
implant is a foreign body in the anterior chamber and lies near the corneal 
endothelium. These attributes are believed to cause the observed endothelial 
loss.[101] However, a subconjunctival mitomycin C (MMC) soak was used in this 
study and MMC is associated corneal endothelial loss.[4, 84] 
Casini et al compared trabeculectomy versus EX-PRESS device versus Ahmed valve 
implant. They followed their cohort for three months. At three months, they recorded 
a 4.2% and 3.5% central corneal endothelial loss in the trabeculectomy group and 
eyes with Ahmed valve implant, respectively. Eyes with EX-PRESS shunt and control 
did not show any significant change in corneal endothelial count at three months It 
was not clear from the article whether MMC was used or not. The authors concluded 
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that the EX-PRESS shunt could be a safer option for eyes with low ECD count. [102] 
This is a very short follow up period and long-term follow-up is necessary in order to 
draw any meaningful conclusions. Another device from Alcon, the CyPass micro-
stent (Alcon Laboratories, Inc, Ft. Worth, TX), was used to shunt aqueous humour 
from the anterior chamber into the supraciliary space as a means to lower IOP. The 
device was subsequently withdrawn from the market, primarily due to significant 
corneal endothelial loss, compared to the control group, that was observed 5 years  
following implantation. [103] 
We found that the tube-corneal angle (TCA) and tube length (TL) were the only 
parameters that were associated with ECD loss in the superio-nasal quadrant. We 
did not find any significant correlation between tube parameters and ECD loss in 
other corneal locations. Lee et al. reported a statistically significant ECD loss in, 
superio-temporally-placed, Ahmed valve eyes at 24 months when compared to 
preoperative measures and controls. The loss was as high as 15.4% and 22.6% in the 
central and superio-temporal corneal areas, respectively.[16] These values are much 
higher than what we have observed but our study lacked preoperative corneal 
parameter measures and merely reported change over time. Similarly, the ECD 
change over the last six months of Lee’s et al. study showed only a 1.3% and 4.1% in 
central and superio-temporal corneal locations, respectively.[16] A similar 
observation was described by Iwasaki et al. where they reported that the highest 
ECD loss of 13.1%, at 12 month post tube insertion, occurred at the quadrant where 
the tube was inserted and 12.1% loss occurred centrally. In terms of tube parameters, 
they also reported a strong negative correlation between TCA and decrease in 
corneal ECD at the quadrant of tube insertion.[104]  
A cross-sectional study examined 39 eyes, with superio-temporal Ahmed valve and 
compared it to 20 controls. The distance between the tip of the tube  and the cornea 
(TCD) was significantly associated with low ECD count.[105] Mendrions et al., did 
not report correlations between any of the tube parameters and central or peripheral 
ECD change.[89] One  can easily  postulate that corneal ECD loss is probably 
attributed to combination of reasons rather than the glaucoma drainage device alone. 
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Nonetheless, the reported values in our study and the aforementioned reports are 
higher (7.2% over six months) than the natural progressive ECD loss which is 
estimated at 0.3-0.6% per year for normal adults.[2, 106] 
Besides the natural decrease with aging, ECD loss is also associated with many other 
factors including high IOP and prior intraocular procedures such as cataract 
extraction and trabeculectomy (with or without anti-fibrotic agents). Previous 
intraocular surgeries such as cataract extraction by phacoemulsification is reported to 
cause between 8 – 11% loss of corneal endothelium measured at 12 months after 
surgery[3] [107] [108] Trabeculectomy with anti-fibrotic agents, such as mitomycin C, 
has also been documented to cause an ECD decrease of 10.6% at 12 months. [109] 
ECD losses after such surgeries are believed to be a one-off event unlike the 
likelihood of progressive loss after glaucoma drainage devices. Another factor that 
contributes to ECD loss is the degree of IOP and the period of sustained IOP 
elevation. One study reported a 33% ECD loss following angle-closure glaucoma 
crises, and as high as a 70% ECD loss for sustained high IOP for 8 days. [110] Thus, it 
was necessary to adjust for confounders such as high IOP and prior intraocular 
surgeries in  our cohort. Both cases and controls groups in our study did not differ in 
the number of prior intraocular surgeries but understandably the Molteno Implant 
group had significantly higher IOP, which necessitated the implant. After adjusting 
for IOP, the observed differences continued to prevail. Univariate regression analysis 
suggests that TCA, TL and the type of glaucoma (particularly chronic narrow angle) 
were the highest predictors of SN ECD loss. To our knowledge, there are no 
published reports from OGSOS or other studies regarding corneal complications 





8.2 Limitations and strengths of study 
One major limitation is the lack of preoperative measures to reflect the true 
endothelial change. The investigator was, also, bound by the ethical approval to 
recruit patients who were attending their planned follow up appointment at the eye 
clinic and could not recall patients specifically for the study. It was observed that the 
ECD counts varied considerably (increased in some cases) and this reflects the 
limited repeatability and reproducibility of the specular microscopy, especially when  
it is used to measure the peripheral cornea. Hara et al. compared the clinical efficacy 
of confocal biomicroscopy with that of non-contact specular microscopy for the 
evaluation of the corneal endothelium. Although clear images of corneal endothelial 
cells, allowing the determination of cell density, were obtained for all eyes evaluated 
by confocal biomicroscopy, clear images were obtained for only 36.4% of these eyes 
by non-contact specular microscopy.[111] Even though, tube length and angle where 
correlated to ECD loss in our study, we could not deduce a recommended tube 
length or tube angulation in the anterior chamber to minimise such ECD loss.  
On the other hand, this study presented the largest cohort of eyes with Molteno 
Glaucoma Implants and the relationship between the tube parameters and changes 
in corneal endothelium. In addition, a no treatment (without Molteno implant) 
control group that was exposed to similar stressors to the cases, added a significant 
value to the study. The use of an appropriate control group (unusual in this kind of 







8.3 Conclusion  
The rate of ECD loss in eye with Molteno implants was comparable to the loss 
observed in the literature for eyes with other glaucoma drainage devices. Tube-
corneal distance was not associated with ECD loss but there was an observed 
detrimental local effect of tube-corneal angle and tube length on the corneal 
endothelium.  The type of glaucoma, degree of IOP elevation and prior intraocular 
surgeries are likely to play a role in ECD loss and may augment any effect from the 
tube itself and the surgery to put it in place. From a clinical perspective, one must 
enlist ancillary tests such as specular microscopy and AS-OCT before embarking on 
Molteno Implant surgery to determine patients at risk of corneal complications.  
 
8.4 Future directions 
It will be valuable to examine the entire OGSOS’s cohort to see if any would develop 
corneal oedema over the coming years. A large prospective study may help to 
determine the actual change in corneal parameters. A study to determine the 
composition of the aqueous humour in glaucoma eyes before and after glaucoma 
surgeries would be useful to identify any contributing factors to the compromise of 
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